"Thiazoles" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Heterocyclic compounds where the ring system is composed of three CARBON atoms, a SULFUR and NITROGEN atoms.
| Descriptor ID |
D013844
|
| MeSH Number(s) |
D02.886.675 D03.383.129.708
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Thiazoles".
Below are MeSH descriptors whose meaning is more specific than "Thiazoles".
This graph shows the total number of publications written about "Thiazoles" by people in this website by year, and whether "Thiazoles" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 1 | 0 | 1 |
| 1997 | 0 | 1 | 1 |
| 1999 | 1 | 1 | 2 |
| 2000 | 2 | 0 | 2 |
| 2001 | 1 | 4 | 5 |
| 2002 | 1 | 1 | 2 |
| 2003 | 1 | 2 | 3 |
| 2004 | 3 | 0 | 3 |
| 2005 | 1 | 3 | 4 |
| 2006 | 1 | 0 | 1 |
| 2007 | 2 | 0 | 2 |
| 2008 | 0 | 1 | 1 |
| 2009 | 3 | 0 | 3 |
| 2010 | 3 | 2 | 5 |
| 2011 | 5 | 1 | 6 |
| 2012 | 4 | 0 | 4 |
| 2013 | 4 | 4 | 8 |
| 2014 | 3 | 0 | 3 |
| 2015 | 2 | 1 | 3 |
| 2016 | 1 | 3 | 4 |
| 2017 | 1 | 2 | 3 |
| 2018 | 2 | 1 | 3 |
| 2019 | 2 | 0 | 2 |
| 2020 | 0 | 1 | 1 |
| 2021 | 0 | 1 | 1 |
| 2022 | 0 | 1 | 1 |
| 2023 | 1 | 1 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Thiazoles" by people in Profiles.
-
NOS inhibition sensitizes metaplastic breast cancer to PI3K inhibition and taxane therapy via c-JUN repression. Nat Commun. 2024 Dec 30; 15(1):10737.
-
Plain language summary of zanubrutinib or ibrutinib in chronic lymphocytic leukemia that is resistant to treatment or has come back after treatment. Future Oncol. 2024 Apr; 20(12):717-726.
-
Short-term PI3K Inhibition Prevents Breast Cancer in Preclinical Models. Cancer Prev Res (Phila). 2023 02 06; 16(2):65-73.
-
Periorbital edema associated with alpelisib. Cancer Treat Res Commun. 2022; 32:100596.
-
Low-Dose Ziprasidone in Combination with Sertraline for First-Episode Drug-Na?ve Patients with Schizophrenia: a Randomized Controlled Trial. Neurotherapeutics. 2022 04; 19(3):1037-1046.
-
Phase 1b Clinical Trial with Alpelisib plus Olaparib for Patients with Advanced Triple-Negative Breast Cancer. Clin Cancer Res. 2022 04 14; 28(8):1493-1499.
-
Therapeutic implications of activating noncanonical PIK3CA mutations in head and neck squamous cell carcinoma. J Clin Invest. 2021 11 15; 131(22).
-
A Phase I Study of LSZ102, an Oral Selective Estrogen Receptor Degrader, with or without Ribociclib or Alpelisib, in Patients with Estrogen Receptor-Positive Breast Cancer. Clin Cancer Res. 2021 11 01; 27(21):5760-5770.
-
Final results of a phase 2 clinical trial of LCL161, an oral SMAC mimetic for patients with myelofibrosis. Blood Adv. 2021 08 24; 5(16):3163-3173.
-
Use of oral anticoagulants in patients with valvular atrial fibrillation: findings from the NCDR PINNACLE Registry. Am Heart J. 2021 10; 240:58-62.